Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Change in Accured Expenses (2016 - 2025)

Biomerica's Change in Accured Expenses history spans 16 years, with the latest figure at -$47000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 840.0% year-over-year to -$47000.0; the TTM value through Nov 2025 reached -$55000.0, down 125.0%, while the annual FY2025 figure was $1000.0, 99.59% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$47000.0 at Biomerica, up from -$63000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $507000.0 in Q2 2025 and bottomed at -$635000.0 in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $7500.0 (2024), against an average of $7694.2.
  • The largest annual shift saw Change in Accured Expenses surged 1399.98% in 2021 before it plummeted 2360.0% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $166605.0 in 2021, then soared by 110.68% to $351000.0 in 2022, then crashed by 56.98% to $151000.0 in 2023, then crashed by 103.31% to -$5000.0 in 2024, then plummeted by 840.0% to -$47000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Change in Accured Expenses are -$47000.0 (Q4 2025), -$63000.0 (Q3 2025), and $507000.0 (Q2 2025).